Lantheus (LNTH) to Release Earnings on Thursday

Lantheus (NASDAQ:LNTH) is projected to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Lantheus to post earnings of $1.28 per share and revenue of $363.4160 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The company had revenue of $92.51 million during the quarter. On average, analysts expect Lantheus to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Lantheus Price Performance

LNTH stock opened at $57.71 on Wednesday. The firm’s 50-day moving average price is $54.19 and its two-hundred day moving average price is $69.25. Lantheus has a 12-month low of $47.25 and a 12-month high of $115.09. The stock has a market capitalization of $3.92 billion, a price-to-earnings ratio of 15.35 and a beta of 0.09. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49.

Insider Activity

In related news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares in the company, valued at $195,246,296.05. This trade represents a 49.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 6,812,000 shares of company stock valued at $382,427,380. 1.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Lantheus

Several large investors have recently bought and sold shares of LNTH. Raymond James Financial Inc. increased its holdings in Lantheus by 25.1% in the 2nd quarter. Raymond James Financial Inc. now owns 470,678 shares of the medical equipment provider’s stock worth $38,530,000 after buying an additional 94,312 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S grew its stake in shares of Lantheus by 191.5% in the second quarter. BI Asset Management Fondsmaeglerselskab A S now owns 97,958 shares of the medical equipment provider’s stock worth $8,019,000 after acquiring an additional 64,358 shares during the period. First Light Asset Management LLC bought a new stake in shares of Lantheus in the second quarter worth approximately $2,459,000. Vident Advisory LLC grew its stake in shares of Lantheus by 46.7% in the second quarter. Vident Advisory LLC now owns 69,575 shares of the medical equipment provider’s stock worth $5,695,000 after acquiring an additional 22,148 shares during the period. Finally, First Trust Advisors LP grew its stake in shares of Lantheus by 37.4% in the second quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock worth $5,714,000 after acquiring an additional 19,008 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on LNTH. TD Cowen decreased their price objective on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, September 15th. B. Riley decreased their price objective on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research report on Tuesday, September 16th. Weiss Ratings lowered shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. JMP Securities decreased their price objective on shares of Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a report on Thursday, August 7th. Finally, William Blair restated a “market perform” rating on shares of Lantheus in a report on Wednesday, July 16th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Lantheus presently has an average rating of “Hold” and a consensus price target of $74.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.